Published in Regen Med Res on January 03, 2014
Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell (2006) 120.51
Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell (2007) 101.42
Bone marrow cells regenerate infarcted myocardium. Nature (2001) 21.24
Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell (2003) 18.09
Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell (2010) 15.58
Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med (2006) 11.66
Concern Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet (2011) 11.45
Evidence that human cardiac myocytes divide after myocardial infarction. N Engl J Med (2001) 10.03
Chimerism of the transplanted heart. N Engl J Med (2002) 8.69
Evidence from a genetic fate-mapping study that stem cells refresh adult mammalian cardiomyocytes after injury. Nat Med (2007) 8.06
Human cardiac stem cells. Proc Natl Acad Sci U S A (2007) 7.76
Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci U S A (2001) 7.19
Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet (2003) 6.85
Stage-specific optimization of activin/nodal and BMP signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines. Cell Stem Cell (2011) 6.71
Conversion of mouse fibroblasts into cardiomyocytes using a direct reprogramming strategy. Nat Cell Biol (2011) 4.64
Cardiac stem cells delivered intravascularly traverse the vessel barrier, regenerate infarcted myocardium, and improve cardiac function. Proc Natl Acad Sci U S A (2005) 3.64
Bone marrow cells differentiate in cardiac cell lineages after infarction independently of cell fusion. Circ Res (2004) 3.39
Cardiomyocyte differentiation of human induced pluripotent stem cells. Circulation (2009) 2.86
Myocyte renewal and ventricular remodelling. Nature (2002) 2.80
Stem cell treatment for acute myocardial infarction. Cochrane Database Syst Rev (2012) 2.78
Induced pluripotent stem cells: the new patient? Nat Rev Mol Cell Biol (2012) 2.50
Stromal cell derived factor-1 alpha confers protection against myocardial ischemia/reperfusion injury: role of the cardiac stromal cell derived factor-1 alpha CXCR4 axis. Circulation (2007) 2.35
VEGF/SDF-1 promotes cardiac stem cell mobilization and myocardial repair in the infarcted heart. Cardiovasc Res (2011) 2.30
Myocyte death, growth, and regeneration in cardiac hypertrophy and failure. Circ Res (2003) 2.26
An efficient nonviral method to generate integration-free human-induced pluripotent stem cells from cord blood and peripheral blood cells. Stem Cells (2013) 2.18
iPS programmed without c-MYC yield proficient cardiogenesis for functional heart chimerism. Circ Res (2009) 1.77
Regeneration of infarcted myocardium by intramyocardial implantation of ex vivo transforming growth factor-beta-preprogrammed bone marrow stem cells. Circulation (2005) 1.70
In vivo differentiation of induced pluripotent stem cell-derived cardiomyocytes. Circ J (2013) 1.55
Diabetic cardiomyopathy: pathophysiology and clinical features. Heart Fail Rev (2013) 1.44
iPS cells: a source of cardiac regeneration. J Mol Cell Cardiol (2010) 1.42
Cell death and diabetic cardiomyopathy. Cardiovasc Toxicol (2003) 1.32
Monocyte-directed RNAi targeting CCR2 improves infarct healing in atherosclerosis-prone mice. Circulation (2013) 1.30
Functional consequences of human induced pluripotent stem cell therapy: myocardial ATP turnover rate in the in vivo swine heart with postinfarction remodeling. Circulation (2013) 1.29
Enhanced survival of transplanted human induced pluripotent stem cell-derived cardiomyocytes by the combination of cell sheets with the pedicled omental flap technique in a porcine heart. Circulation (2013) 1.28
Pluripotent stem cell-engineered cell sheets reassembled with defined cardiovascular populations ameliorate reduction in infarct heart function through cardiomyocyte-mediated neovascularization. Stem Cells (2012) 1.27
Myocardial structure, function, and scar in patients with type 1 diabetes mellitus. Circulation (2011) 1.20
Developmental and regenerative biology of multipotent cardiovascular progenitor cells. Circ Res (2011) 1.16
Induced pluripotent stem (iPS) cells repair and regenerate infarcted myocardium. Mol Pharm (2011) 1.12
High-purity enrichment of functional cardiovascular cells from human iPS cells. Cardiovasc Res (2012) 1.07
Overexpression of angiopoietin-1 increases CD133+/c-kit+ cells and reduces myocardial apoptosis in db/db mouse infarcted hearts. PLoS One (2012) 1.06
Improved anti-apoptotic and anti-remodeling potency of bone marrow mesenchymal stem cells by anoxic pre-conditioning in diabetic cardiomyopathy. J Endocrinol Invest (2008) 1.05
Type 2 diabetes restricts multipotency of mesenchymal stem cells and impairs their capacity to augment postischemic neovascularization in db/db mice. J Am Heart Assoc (2012) 1.03
The role of CXCR7 on the adhesion, proliferation and angiogenesis of endothelial progenitor cells. J Cell Mol Med (2011) 1.03
Impaired muscle regeneration in ob/ob and db/db mice. ScientificWorldJournal (2011) 1.02
Induced pluripotent stem cell-derived cardiac progenitors differentiate to cardiomyocytes and form biosynthetic tissues. PLoS One (2013) 1.00
Nanoparticle based delivery of hypoxia-regulated VEGF transgene system combined with myoblast engraftment for myocardial repair. Biomaterials (2011) 0.94
Trichostatin A enhances differentiation of human induced pluripotent stem cells to cardiogenic cells for cardiac tissue engineering. Stem Cells Transl Med (2013) 0.94
A novel CXCR4 antagonist derived from human SDF-1beta enhances angiogenesis in ischaemic mice. Cardiovasc Res (2009) 0.93
Bone marrow progenitor cell therapy-mediated paracrine regulation of cardiac miRNA-155 modulates fibrotic response in diabetic hearts. PLoS One (2013) 0.93
Bone marrow mesenchymal stem cells induce angiogenesis and attenuate the remodeling of diabetic cardiomyopathy. Exp Clin Endocrinol Diabetes (2008) 0.93
Effect of bone marrow-derived mesenchymal stem cells on cardiovascular complications in diabetic rats. Med Sci Monit (2008) 0.92
Transplanted induced pluripotent stem cells improve cardiac function and induce neovascularization in the infarcted hearts of db/db mice. Mol Pharm (2011) 0.88
Meta-analysis of stem cell therapy in chronic ischemic cardiomyopathy. Am J Cardiol (2013) 0.87
Intramuscular VEGF activates an SDF1-dependent progenitor cell cascade and an SDF1-independent muscle paracrine cascade for cardiac repair. Am J Physiol Heart Circ Physiol (2011) 0.87
Cloning and characterizing mutated human stromal cell-derived factor-1 (SDF-1): C-terminal alpha-helix of SDF-1alpha plays a critical role in CXCR4 activation and signaling, but not in CXCR4 binding affinity. Exp Hematol (2006) 0.87
Induced pluripotent stem cells for cardiac repair. Cell Mol Life Sci (2012) 0.86
Poor glycaemic control in type 2 diabetes patients reduces endothelial progenitor cell number by influencing SIRT1 signalling via platelet-activating factor receptor activation. Diabetologia (2012) 0.86
Effect of high glucose on extensive culturing of mesenchymal stem cells derived from subcutaneous fat, omentum fat and bone marrow. Cell Biochem Funct (2012) 0.86
Abnormalities of the cardiac stem and progenitor cell compartment in experimental and human diabetes. Arch Physiol Biochem (2013) 0.85
Increased survival of haemopoietic pluripotent stem cells in vitro induced by a marrow fibroblast factor. Br J Haematol (1977) 0.83
Downregulated microRNA-32 expression induced by high glucose inhibits cell cycle progression via PTEN upregulation and Akt inactivation in bone marrow-derived mesenchymal stem cells. Biochem Biophys Res Commun (2013) 0.83
The response of the atrium to direct mechanical wounding in the adult heart of the newt, Notophthalmus viridescens. An electron-microscopic and autoradiographic study. Cell Tissue Res (1984) 0.83
Preconditioning diabetic mesenchymal stem cells with myogenic medium increases their ability to repair diabetic heart. Stem Cell Res Ther (2013) 0.82
Mesenchymal stem cell therapy improves diabetic cardiac autonomic neuropathy and decreases the inducibility of ventricular arrhythmias. Heart Lung Circ (2013) 0.82
Transplanted induced pluripotent stem cells mitigate oxidative stress and improve cardiac function through the Akt cell survival pathway in diabetic cardiomyopathy. Mol Pharm (2013) 0.82
Functional regeneration of ischemic myocardium by transplanted cells overexpressing stromal cell-derived factor-1 (SDF-1): intramyocardial injection versus scaffold-based application. Eur J Cardiothorac Surg (2011) 0.81
Poor functional recovery after transplantation of diabetic bone marrow stem cells in ischemic myocardium. J Heart Lung Transplant (2009) 0.81
Hyperglycaemia exerts deleterious effects on late endothelial progenitor cell secretion actions. Diab Vasc Dis Res (2012) 0.81
Impaired cardioprotective function of transplantation of mesenchymal stem cells from patients with diabetes mellitus to rats with experimentally induced myocardial infarction. Cardiovasc Diabetol (2013) 0.81
Stem cells in the diabetic infarcted heart. Heart Fail Rev (2010) 0.80
Myocardial repair and regeneration: bone marrow or cardiac stem cells? Mol Ther (2012) 0.80
Hyperglycemia suppresses cardiac stem cell homing to peri-infarcted myocardium via regulation of ERK1/2 and p38 MAPK activities. Int J Mol Med (2012) 0.78
Advances in culture and manipulation of human pluripotent stem cells. J Dent Res (2013) 0.78
Gender differences in clinical outcomes among diabetic patients hospitalized for cardiovascular disease. Am Heart J (2013) 0.78
The atrial proliferative response following partial ventricular amputation in the heart of the adult newt. A light and electron microscopic autoradiographic study. Tissue Cell (1983) 0.76
Regenerative therapies for improving myocardial perfusion in patients with cardiovascular disease: failure to meet expectations but optimism for the future. Curr Vasc Pharmacol (2012) 0.76